Rdhilly的个人主页 - 老虎社区

Rdhilly

Rdhilly

暂无个人介绍

IP属地：未知

33关注

0粉丝

0主题

0勋章

2021-09-24

.

Why Novavax Stock Is Jumping Today

2021-09-21

.

Why Nio Shares Are Falling

2021-09-10

.

White House Will Announce Drug-Pricing Plan, WSJ Says. Pharma Stocks Are Down.

2021-09-10

.

抱歉，原内容已删除

2021-09-10

.

抱歉，原内容已删除

去老虎APP查看更多动态

{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":"3576861864918846","uuid":"3576861864918846","gmtCreate":1613767841346,"gmtModify":1632402691911,"name":"Rdhilly","pinyin":"rdhilly","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/d00424543e3f5db74636158d0166cd42","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":0,"headSize":33,"tweetSize":5,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"35ec162348d5460f88c959321e554969-3","templateUuid":"35ec162348d5460f88c959321e554969","name":"传说交易员","description":"证券或期货账户累计交易次数达到300次","bigImgUrl":"https://static.tigerbbs.com/656db16598a0b8f21429e10d6c1cb033","smallImgUrl":"https://static.tigerbbs.com/03f10910d4dd9234f9b5702a3342193a","grayImgUrl":"https://static.tigerbbs.com/0c767e35268feb729d50d3fa9a386c5a","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.03.23","exceedPercentage":"93.54%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-1","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"出道虎友","description":"加入老虎社区500天","bigImgUrl":"https://static.tigerbbs.com/0e4d0ca1da0456dc7894c946d44bf9ab","smallImgUrl":"https://static.tigerbbs.com/0f2f65e8ce4cfaae8db2bea9b127f58b","grayImgUrl":"https://static.tigerbbs.com/c5948a31b6edf154422335b265235809","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.07.08","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.28","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":4,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":5,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":861979908,"gmtCreate":1632452042704,"gmtModify":1632722226764,"author":{"id":"3576861864918846","authorId":"3576861864918846","name":"Rdhilly","avatar":"https://static.tigerbbs.com/d00424543e3f5db74636158d0166cd42","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3576861864918846","authorIdStr":"3576861864918846"},"themes":[],"htmlText":".","listText":".","text":".","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/861979908","repostId":"2169698119","repostType":4,"repost":{"id":"2169698119","kind":"highlight","pubTimestamp":1632450780,"share":"https://ttm.financial/m/news/2169698119?lang=&edition=full","pubTime":"2021-09-24 10:33","market":"us","language":"en","title":"Why Novavax Stock Is Jumping Today","url":"https://stock-news.laohu8.com/highlight/detail?id=2169698119","media":"Motley Fool","summary":"There were two positive news stories for the biotech on Thursday.","content":"<h2>What happened</h2>\n<p>Shares of <b>Novavax</b> (NASDAQ:NVAX) were jumping 9.7% as of 10:48 a.m. EDT on Thursday. There were a couple of catalysts for the stock.</p>\n<p>Novavax and its partner, Serum Institute of India, announced Thursday morning that they have filed for World Health Organization emergency use listing of Novavax's COVID-19 vaccine. Also, data from a late-stage clinical study conducted in the U.K. of the vaccine were published in The New England Journal of Medicine. This data showed that Novavax's vaccine achieved an efficacy of 89.7%.</p>\n<h2>So what</h2>\n<p>Neither of today's developments was a surprise. However, they were both positive for Novavax and motivated some investors to pile back into the vaccine stock.</p>\n<p>Of the two stories, the EUL filing is the more important for Novavax. An EUL from the WHO is needed to export vaccines to countries that participate in the COVAX Facility. Novavax CEO Stanley Erck stated, \"Today's submission of our protein-based COVID-19 vaccine to WHO for emergency use listing is a significant step on the path to accelerating access and more equitable distribution to countries in great need around the world.\"</p>\n<h2>Now what</h2>\n<p>It's uncertain how long the WHO will take to complete its review of Novavax's and SII's EUL filing. In the meantime, investors can look forward to several other key milestones. Novavax is preparing to file for emergency use authorizations in several countries, including the U.K., Canada, Australia, New Zealand, the European Union, and the U.S.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Novavax Stock Is Jumping Today</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Novavax Stock Is Jumping Today\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-24 10:33 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/09/23/why-novavax-stock-is-jumping-today/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>What happened\nShares of Novavax (NASDAQ:NVAX) were jumping 9.7% as of 10:48 a.m. EDT on Thursday. There were a couple of catalysts for the stock.\nNovavax and its partner, Serum Institute of India, ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/09/23/why-novavax-stock-is-jumping-today/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"source_url":"https://www.fool.com/investing/2021/09/23/why-novavax-stock-is-jumping-today/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2169698119","content_text":"What happened\nShares of Novavax (NASDAQ:NVAX) were jumping 9.7% as of 10:48 a.m. EDT on Thursday. There were a couple of catalysts for the stock.\nNovavax and its partner, Serum Institute of India, announced Thursday morning that they have filed for World Health Organization emergency use listing of Novavax's COVID-19 vaccine. Also, data from a late-stage clinical study conducted in the U.K. of the vaccine were published in The New England Journal of Medicine. This data showed that Novavax's vaccine achieved an efficacy of 89.7%.\nSo what\nNeither of today's developments was a surprise. However, they were both positive for Novavax and motivated some investors to pile back into the vaccine stock.\nOf the two stories, the EUL filing is the more important for Novavax. An EUL from the WHO is needed to export vaccines to countries that participate in the COVAX Facility. Novavax CEO Stanley Erck stated, \"Today's submission of our protein-based COVID-19 vaccine to WHO for emergency use listing is a significant step on the path to accelerating access and more equitable distribution to countries in great need around the world.\"\nNow what\nIt's uncertain how long the WHO will take to complete its review of Novavax's and SII's EUL filing. In the meantime, investors can look forward to several other key milestones. Novavax is preparing to file for emergency use authorizations in several countries, including the U.K., Canada, Australia, New Zealand, the European Union, and the U.S.","news_type":1,"symbols_score_info":{"NVAX":0.9}},"isVote":1,"tweetType":1,"viewCount":2106,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":860522866,"gmtCreate":1632190024355,"gmtModify":1632802179987,"author":{"id":"3576861864918846","authorId":"3576861864918846","name":"Rdhilly","avatar":"https://static.tigerbbs.com/d00424543e3f5db74636158d0166cd42","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3576861864918846","authorIdStr":"3576861864918846"},"themes":[],"htmlText":".","listText":".","text":".","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/860522866","repostId":"1134395057","repostType":4,"repost":{"id":"1134395057","kind":"news","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1632154991,"share":"https://ttm.financial/m/news/1134395057?lang=&edition=full","pubTime":"2021-09-21 00:23","market":"us","language":"en","title":"Why Nio Shares Are Falling","url":"https://stock-news.laohu8.com/highlight/detail?id=1134395057","media":"Benzinga","summary":"Shares of several Chinese companies, includingNio Inc - ADR\nNIO+5.75%(Get Free Alerts for NIO), are ","content":"<p>Shares of several Chinese companies, including<b>Nio Inc - ADR</b></p>\n<p>NIO+5.75%(Get Free Alerts for NIO),&nbsp;are trading lower as investors weigh the possible default of major China-based real estate company Evergrande Group.</p>\n<p>Nio is trading lower by 7.7% over the past five sessions as stocks also pull back amid August strength.</p>\n<p>Nio&nbsp;operates in China's premium electric vehicle market. The company designs and jointly manufactures, and sells smart and connected premium electric vehicles, driving innovations in next-generation technologies in connectivity, autonomous driving&nbsp;and artificial intelligence.</p>\n<p>Nio is trading lower by 5.3% at $35.54. Nio has a 52-week high of $66.99 and a 52-week low of $16.75.</p>\n<p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Nio Shares Are Falling</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Nio Shares Are Falling\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2021-09-21 00:23</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of several Chinese companies, including<b>Nio Inc - ADR</b></p>\n<p>NIO+5.75%(Get Free Alerts for NIO),&nbsp;are trading lower as investors weigh the possible default of major China-based real estate company Evergrande Group.</p>\n<p>Nio is trading lower by 7.7% over the past five sessions as stocks also pull back amid August strength.</p>\n<p>Nio&nbsp;operates in China's premium electric vehicle market. The company designs and jointly manufactures, and sells smart and connected premium electric vehicles, driving innovations in next-generation technologies in connectivity, autonomous driving&nbsp;and artificial intelligence.</p>\n<p>Nio is trading lower by 5.3% at $35.54. Nio has a 52-week high of $66.99 and a 52-week low of $16.75.</p>\n<p></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NIO":"蔚来"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1134395057","content_text":"Shares of several Chinese companies, includingNio Inc - ADR\nNIO+5.75%(Get Free Alerts for NIO), are trading lower as investors weigh the possible default of major China-based real estate company Evergrande Group.\nNio is trading lower by 7.7% over the past five sessions as stocks also pull back amid August strength.\nNio operates in China's premium electric vehicle market. The company designs and jointly manufactures, and sells smart and connected premium electric vehicles, driving innovations in next-generation technologies in connectivity, autonomous driving and artificial intelligence.\nNio is trading lower by 5.3% at $35.54. Nio has a 52-week high of $66.99 and a 52-week low of $16.75.","news_type":1,"symbols_score_info":{"NIO":0.9}},"isVote":1,"tweetType":1,"viewCount":868,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":883190528,"gmtCreate":1631220204964,"gmtModify":1632883914426,"author":{"id":"3576861864918846","authorId":"3576861864918846","name":"Rdhilly","avatar":"https://static.tigerbbs.com/d00424543e3f5db74636158d0166cd42","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3576861864918846","authorIdStr":"3576861864918846"},"themes":[],"htmlText":".","listText":".","text":".","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/883190528","repostId":"1176976417","repostType":4,"repost":{"id":"1176976417","kind":"news","pubTimestamp":1631197026,"share":"https://ttm.financial/m/news/1176976417?lang=&edition=full","pubTime":"2021-09-09 22:17","market":"us","language":"en","title":"White House Will Announce Drug-Pricing Plan, WSJ Says. Pharma Stocks Are Down.","url":"https://stock-news.laohu8.com/highlight/detail?id=1176976417","media":"Barron's","summary":"The White House is set to lay out a plan on Thursday to cut prices for prescription drugs, according","content":"<p>The White House is set to lay out a plan on Thursday to cut prices for prescription drugs, according to a report out early Thursday from <i>The Wall Street Journal</i>.</p>\n<p>The plan will allow Medicare to negotiate on drug pricing, and would allow the Department of Health and Human Services to test linking payments for drugs to how the drugs benefit patients, according to the <i>Journal</i> report.</p>\n<p>The plan would come amid an effort from Congressional Democrats to enact drug-pricing legislation. Both parties have supported efforts to cut prescription- drug prices, though the Trump administration made little progress on the issue.</p>\n<p>The S&amp;P 500 Pharmaceuticals index is up 14.9% so far this year, trailing behind the broader S&amp;P 500,&nbsp;which has risen 20.2%. The SPDR S&amp;P Biotech</p>\n<p>exchange- traded fund (ticker: XBI), which largely tracks the small and midcap biotech sector, has declined 6% over the same period.</p>\n<p>Shares of pharma firms were down in the early morning on Thursday. Pfizer (PFE) shares were down 0.26% in early trading, while Eli Lilly(LLY) shares were down 2.46%, Merck (MRK) shares fell 1.17%, and Johnson &amp; Johnson&nbsp;(JNJ) shares declined 0.7%.</p>\n<p><img src=\"https://static.tigerbbs.com/1f3b476333002ca1b549be932aa2a442\" tg-width=\"275\" tg-height=\"163\" width=\"100%\" height=\"auto\"></p>\n<p>Worries over efforts to limit drug prices have been a long-term overhang on the biotech and pharmaceutical industries. Some analysts have suggested that renewed concerns over drug-price legislation could be one driver behind the recent weakness in biotech stocks.</p>\n<p>According to the <i>Journal</i>, the pharmaceutical industry trade group PhRMA is pushing back against the reported White House proposal, and the Democrats’ efforts in Congress, saying on a press call on Wednesday that allowing Medicare to negotiate for drug pricing would mean less money to fund the development of new drugs.</p>\n<p>“The proposals that we’re seeing from Congress will devastate this industry,” Merck chairman Kenneth Frazier said on the press call, according to a report from the news outlet Fierce Pharma, which tracks the industry. “While large companies like Merck will survive, we will do significantly less research.”</p>\n<p>Lilly CEO David Ricks also spoke on the call.</p>\n<p>“From the drug industry perspective, the creation of a price negotiation mechanism would be a material negative (as its role may expand over time),” Bernstein analyst Ronny Gal wrote in a note out Tuesday.</p>\n<p>In addition to the drug-pricing plan, the <i>New York Times</i> reported that President Biden will announce a plan on Thursday to push businesses, schools, and the federal government to adopt strict vaccination policies.</p>","source":"lsy1610680873436","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>White House Will Announce Drug-Pricing Plan, WSJ Says. Pharma Stocks Are Down. </title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhite House Will Announce Drug-Pricing Plan, WSJ Says. Pharma Stocks Are Down. \n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-09 22:17 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.marketwatch.com/articles/white-house-drug-pricing-pharma-stocks-51631195642?mod=mw_latestnews><strong>Barron's</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The White House is set to lay out a plan on Thursday to cut prices for prescription drugs, according to a report out early Thursday from The Wall Street Journal.\nThe plan will allow Medicare to ...</p>\n\n<a href=\"https://www.marketwatch.com/articles/white-house-drug-pricing-pharma-stocks-51631195642?mod=mw_latestnews\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LLY":"礼来","PFE":"辉瑞","JNJ":"强生"},"source_url":"https://www.marketwatch.com/articles/white-house-drug-pricing-pharma-stocks-51631195642?mod=mw_latestnews","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1176976417","content_text":"The White House is set to lay out a plan on Thursday to cut prices for prescription drugs, according to a report out early Thursday from The Wall Street Journal.\nThe plan will allow Medicare to negotiate on drug pricing, and would allow the Department of Health and Human Services to test linking payments for drugs to how the drugs benefit patients, according to the Journal report.\nThe plan would come amid an effort from Congressional Democrats to enact drug-pricing legislation. Both parties have supported efforts to cut prescription- drug prices, though the Trump administration made little progress on the issue.\nThe S&P 500 Pharmaceuticals index is up 14.9% so far this year, trailing behind the broader S&P 500, which has risen 20.2%. The SPDR S&P Biotech\nexchange- traded fund (ticker: XBI), which largely tracks the small and midcap biotech sector, has declined 6% over the same period.\nShares of pharma firms were down in the early morning on Thursday. Pfizer (PFE) shares were down 0.26% in early trading, while Eli Lilly(LLY) shares were down 2.46%, Merck (MRK) shares fell 1.17%, and Johnson & Johnson (JNJ) shares declined 0.7%.\n\nWorries over efforts to limit drug prices have been a long-term overhang on the biotech and pharmaceutical industries. Some analysts have suggested that renewed concerns over drug-price legislation could be one driver behind the recent weakness in biotech stocks.\nAccording to the Journal, the pharmaceutical industry trade group PhRMA is pushing back against the reported White House proposal, and the Democrats’ efforts in Congress, saying on a press call on Wednesday that allowing Medicare to negotiate for drug pricing would mean less money to fund the development of new drugs.\n“The proposals that we’re seeing from Congress will devastate this industry,” Merck chairman Kenneth Frazier said on the press call, according to a report from the news outlet Fierce Pharma, which tracks the industry. “While large companies like Merck will survive, we will do significantly less research.”\nLilly CEO David Ricks also spoke on the call.\n“From the drug industry perspective, the creation of a price negotiation mechanism would be a material negative (as its role may expand over time),” Bernstein analyst Ronny Gal wrote in a note out Tuesday.\nIn addition to the drug-pricing plan, the New York Times reported that President Biden will announce a plan on Thursday to push businesses, schools, and the federal government to adopt strict vaccination policies.","news_type":1,"symbols_score_info":{"JNJ":0.9,"LLY":0.9,"PFE":0.9}},"isVote":1,"tweetType":1,"viewCount":1821,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":883190234,"gmtCreate":1631220170528,"gmtModify":1632883914550,"author":{"id":"3576861864918846","authorId":"3576861864918846","name":"Rdhilly","avatar":"https://static.tigerbbs.com/d00424543e3f5db74636158d0166cd42","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3576861864918846","authorIdStr":"3576861864918846"},"themes":[],"htmlText":".","listText":".","text":".","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/883190234","repostId":"2166854349","repostType":4,"isVote":1,"tweetType":1,"viewCount":1716,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":883190863,"gmtCreate":1631220142352,"gmtModify":1632883914670,"author":{"id":"3576861864918846","authorId":"3576861864918846","name":"Rdhilly","avatar":"https://static.tigerbbs.com/d00424543e3f5db74636158d0166cd42","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3576861864918846","authorIdStr":"3576861864918846"},"themes":[],"htmlText":".","listText":".","text":".","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/883190863","repostId":"2166854349","repostType":4,"isVote":1,"tweetType":1,"viewCount":1286,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":883190528,"gmtCreate":1631220204964,"gmtModify":1632883914426,"author":{"id":"3576861864918846","authorId":"3576861864918846","name":"Rdhilly","avatar":"https://static.tigerbbs.com/d00424543e3f5db74636158d0166cd42","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3576861864918846","authorIdStr":"3576861864918846"},"themes":[],"htmlText":".","listText":".","text":".","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/883190528","repostId":"1176976417","repostType":4,"repost":{"id":"1176976417","kind":"news","pubTimestamp":1631197026,"share":"https://ttm.financial/m/news/1176976417?lang=&edition=full","pubTime":"2021-09-09 22:17","market":"us","language":"en","title":"White House Will Announce Drug-Pricing Plan, WSJ Says. Pharma Stocks Are Down.","url":"https://stock-news.laohu8.com/highlight/detail?id=1176976417","media":"Barron's","summary":"The White House is set to lay out a plan on Thursday to cut prices for prescription drugs, according","content":"<p>The White House is set to lay out a plan on Thursday to cut prices for prescription drugs, according to a report out early Thursday from <i>The Wall Street Journal</i>.</p>\n<p>The plan will allow Medicare to negotiate on drug pricing, and would allow the Department of Health and Human Services to test linking payments for drugs to how the drugs benefit patients, according to the <i>Journal</i> report.</p>\n<p>The plan would come amid an effort from Congressional Democrats to enact drug-pricing legislation. Both parties have supported efforts to cut prescription- drug prices, though the Trump administration made little progress on the issue.</p>\n<p>The S&amp;P 500 Pharmaceuticals index is up 14.9% so far this year, trailing behind the broader S&amp;P 500,&nbsp;which has risen 20.2%. The SPDR S&amp;P Biotech</p>\n<p>exchange- traded fund (ticker: XBI), which largely tracks the small and midcap biotech sector, has declined 6% over the same period.</p>\n<p>Shares of pharma firms were down in the early morning on Thursday. Pfizer (PFE) shares were down 0.26% in early trading, while Eli Lilly(LLY) shares were down 2.46%, Merck (MRK) shares fell 1.17%, and Johnson &amp; Johnson&nbsp;(JNJ) shares declined 0.7%.</p>\n<p><img src=\"https://static.tigerbbs.com/1f3b476333002ca1b549be932aa2a442\" tg-width=\"275\" tg-height=\"163\" width=\"100%\" height=\"auto\"></p>\n<p>Worries over efforts to limit drug prices have been a long-term overhang on the biotech and pharmaceutical industries. Some analysts have suggested that renewed concerns over drug-price legislation could be one driver behind the recent weakness in biotech stocks.</p>\n<p>According to the <i>Journal</i>, the pharmaceutical industry trade group PhRMA is pushing back against the reported White House proposal, and the Democrats’ efforts in Congress, saying on a press call on Wednesday that allowing Medicare to negotiate for drug pricing would mean less money to fund the development of new drugs.</p>\n<p>“The proposals that we’re seeing from Congress will devastate this industry,” Merck chairman Kenneth Frazier said on the press call, according to a report from the news outlet Fierce Pharma, which tracks the industry. “While large companies like Merck will survive, we will do significantly less research.”</p>\n<p>Lilly CEO David Ricks also spoke on the call.</p>\n<p>“From the drug industry perspective, the creation of a price negotiation mechanism would be a material negative (as its role may expand over time),” Bernstein analyst Ronny Gal wrote in a note out Tuesday.</p>\n<p>In addition to the drug-pricing plan, the <i>New York Times</i> reported that President Biden will announce a plan on Thursday to push businesses, schools, and the federal government to adopt strict vaccination policies.</p>","source":"lsy1610680873436","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>White House Will Announce Drug-Pricing Plan, WSJ Says. Pharma Stocks Are Down. </title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhite House Will Announce Drug-Pricing Plan, WSJ Says. Pharma Stocks Are Down. \n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-09 22:17 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.marketwatch.com/articles/white-house-drug-pricing-pharma-stocks-51631195642?mod=mw_latestnews><strong>Barron's</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The White House is set to lay out a plan on Thursday to cut prices for prescription drugs, according to a report out early Thursday from The Wall Street Journal.\nThe plan will allow Medicare to ...</p>\n\n<a href=\"https://www.marketwatch.com/articles/white-house-drug-pricing-pharma-stocks-51631195642?mod=mw_latestnews\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LLY":"礼来","PFE":"辉瑞","JNJ":"强生"},"source_url":"https://www.marketwatch.com/articles/white-house-drug-pricing-pharma-stocks-51631195642?mod=mw_latestnews","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1176976417","content_text":"The White House is set to lay out a plan on Thursday to cut prices for prescription drugs, according to a report out early Thursday from The Wall Street Journal.\nThe plan will allow Medicare to negotiate on drug pricing, and would allow the Department of Health and Human Services to test linking payments for drugs to how the drugs benefit patients, according to the Journal report.\nThe plan would come amid an effort from Congressional Democrats to enact drug-pricing legislation. Both parties have supported efforts to cut prescription- drug prices, though the Trump administration made little progress on the issue.\nThe S&P 500 Pharmaceuticals index is up 14.9% so far this year, trailing behind the broader S&P 500, which has risen 20.2%. The SPDR S&P Biotech\nexchange- traded fund (ticker: XBI), which largely tracks the small and midcap biotech sector, has declined 6% over the same period.\nShares of pharma firms were down in the early morning on Thursday. Pfizer (PFE) shares were down 0.26% in early trading, while Eli Lilly(LLY) shares were down 2.46%, Merck (MRK) shares fell 1.17%, and Johnson & Johnson (JNJ) shares declined 0.7%.\n\nWorries over efforts to limit drug prices have been a long-term overhang on the biotech and pharmaceutical industries. Some analysts have suggested that renewed concerns over drug-price legislation could be one driver behind the recent weakness in biotech stocks.\nAccording to the Journal, the pharmaceutical industry trade group PhRMA is pushing back against the reported White House proposal, and the Democrats’ efforts in Congress, saying on a press call on Wednesday that allowing Medicare to negotiate for drug pricing would mean less money to fund the development of new drugs.\n“The proposals that we’re seeing from Congress will devastate this industry,” Merck chairman Kenneth Frazier said on the press call, according to a report from the news outlet Fierce Pharma, which tracks the industry. “While large companies like Merck will survive, we will do significantly less research.”\nLilly CEO David Ricks also spoke on the call.\n“From the drug industry perspective, the creation of a price negotiation mechanism would be a material negative (as its role may expand over time),” Bernstein analyst Ronny Gal wrote in a note out Tuesday.\nIn addition to the drug-pricing plan, the New York Times reported that President Biden will announce a plan on Thursday to push businesses, schools, and the federal government to adopt strict vaccination policies.","news_type":1,"symbols_score_info":{"JNJ":0.9,"LLY":0.9,"PFE":0.9}},"isVote":1,"tweetType":1,"viewCount":1821,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":860522866,"gmtCreate":1632190024355,"gmtModify":1632802179987,"author":{"id":"3576861864918846","authorId":"3576861864918846","name":"Rdhilly","avatar":"https://static.tigerbbs.com/d00424543e3f5db74636158d0166cd42","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3576861864918846","authorIdStr":"3576861864918846"},"themes":[],"htmlText":".","listText":".","text":".","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/860522866","repostId":"1134395057","repostType":4,"repost":{"id":"1134395057","kind":"news","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1632154991,"share":"https://ttm.financial/m/news/1134395057?lang=&edition=full","pubTime":"2021-09-21 00:23","market":"us","language":"en","title":"Why Nio Shares Are Falling","url":"https://stock-news.laohu8.com/highlight/detail?id=1134395057","media":"Benzinga","summary":"Shares of several Chinese companies, includingNio Inc - ADR\nNIO+5.75%(Get Free Alerts for NIO), are ","content":"<p>Shares of several Chinese companies, including<b>Nio Inc - ADR</b></p>\n<p>NIO+5.75%(Get Free Alerts for NIO),&nbsp;are trading lower as investors weigh the possible default of major China-based real estate company Evergrande Group.</p>\n<p>Nio is trading lower by 7.7% over the past five sessions as stocks also pull back amid August strength.</p>\n<p>Nio&nbsp;operates in China's premium electric vehicle market. The company designs and jointly manufactures, and sells smart and connected premium electric vehicles, driving innovations in next-generation technologies in connectivity, autonomous driving&nbsp;and artificial intelligence.</p>\n<p>Nio is trading lower by 5.3% at $35.54. Nio has a 52-week high of $66.99 and a 52-week low of $16.75.</p>\n<p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Nio Shares Are Falling</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Nio Shares Are Falling\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2021-09-21 00:23</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of several Chinese companies, including<b>Nio Inc - ADR</b></p>\n<p>NIO+5.75%(Get Free Alerts for NIO),&nbsp;are trading lower as investors weigh the possible default of major China-based real estate company Evergrande Group.</p>\n<p>Nio is trading lower by 7.7% over the past five sessions as stocks also pull back amid August strength.</p>\n<p>Nio&nbsp;operates in China's premium electric vehicle market. The company designs and jointly manufactures, and sells smart and connected premium electric vehicles, driving innovations in next-generation technologies in connectivity, autonomous driving&nbsp;and artificial intelligence.</p>\n<p>Nio is trading lower by 5.3% at $35.54. Nio has a 52-week high of $66.99 and a 52-week low of $16.75.</p>\n<p></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NIO":"蔚来"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1134395057","content_text":"Shares of several Chinese companies, includingNio Inc - ADR\nNIO+5.75%(Get Free Alerts for NIO), are trading lower as investors weigh the possible default of major China-based real estate company Evergrande Group.\nNio is trading lower by 7.7% over the past five sessions as stocks also pull back amid August strength.\nNio operates in China's premium electric vehicle market. The company designs and jointly manufactures, and sells smart and connected premium electric vehicles, driving innovations in next-generation technologies in connectivity, autonomous driving and artificial intelligence.\nNio is trading lower by 5.3% at $35.54. Nio has a 52-week high of $66.99 and a 52-week low of $16.75.","news_type":1,"symbols_score_info":{"NIO":0.9}},"isVote":1,"tweetType":1,"viewCount":868,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":883190234,"gmtCreate":1631220170528,"gmtModify":1632883914550,"author":{"id":"3576861864918846","authorId":"3576861864918846","name":"Rdhilly","avatar":"https://static.tigerbbs.com/d00424543e3f5db74636158d0166cd42","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3576861864918846","authorIdStr":"3576861864918846"},"themes":[],"htmlText":".","listText":".","text":".","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/883190234","repostId":"2166854349","repostType":4,"isVote":1,"tweetType":1,"viewCount":1716,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":883190863,"gmtCreate":1631220142352,"gmtModify":1632883914670,"author":{"id":"3576861864918846","authorId":"3576861864918846","name":"Rdhilly","avatar":"https://static.tigerbbs.com/d00424543e3f5db74636158d0166cd42","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3576861864918846","authorIdStr":"3576861864918846"},"themes":[],"htmlText":".","listText":".","text":".","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/883190863","repostId":"2166854349","repostType":4,"isVote":1,"tweetType":1,"viewCount":1286,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":861979908,"gmtCreate":1632452042704,"gmtModify":1632722226764,"author":{"id":"3576861864918846","authorId":"3576861864918846","name":"Rdhilly","avatar":"https://static.tigerbbs.com/d00424543e3f5db74636158d0166cd42","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3576861864918846","authorIdStr":"3576861864918846"},"themes":[],"htmlText":".","listText":".","text":".","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/861979908","repostId":"2169698119","repostType":4,"repost":{"id":"2169698119","kind":"highlight","pubTimestamp":1632450780,"share":"https://ttm.financial/m/news/2169698119?lang=&edition=full","pubTime":"2021-09-24 10:33","market":"us","language":"en","title":"Why Novavax Stock Is Jumping Today","url":"https://stock-news.laohu8.com/highlight/detail?id=2169698119","media":"Motley Fool","summary":"There were two positive news stories for the biotech on Thursday.","content":"<h2>What happened</h2>\n<p>Shares of <b>Novavax</b> (NASDAQ:NVAX) were jumping 9.7% as of 10:48 a.m. EDT on Thursday. There were a couple of catalysts for the stock.</p>\n<p>Novavax and its partner, Serum Institute of India, announced Thursday morning that they have filed for World Health Organization emergency use listing of Novavax's COVID-19 vaccine. Also, data from a late-stage clinical study conducted in the U.K. of the vaccine were published in The New England Journal of Medicine. This data showed that Novavax's vaccine achieved an efficacy of 89.7%.</p>\n<h2>So what</h2>\n<p>Neither of today's developments was a surprise. However, they were both positive for Novavax and motivated some investors to pile back into the vaccine stock.</p>\n<p>Of the two stories, the EUL filing is the more important for Novavax. An EUL from the WHO is needed to export vaccines to countries that participate in the COVAX Facility. Novavax CEO Stanley Erck stated, \"Today's submission of our protein-based COVID-19 vaccine to WHO for emergency use listing is a significant step on the path to accelerating access and more equitable distribution to countries in great need around the world.\"</p>\n<h2>Now what</h2>\n<p>It's uncertain how long the WHO will take to complete its review of Novavax's and SII's EUL filing. In the meantime, investors can look forward to several other key milestones. Novavax is preparing to file for emergency use authorizations in several countries, including the U.K., Canada, Australia, New Zealand, the European Union, and the U.S.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Novavax Stock Is Jumping Today</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Novavax Stock Is Jumping Today\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-24 10:33 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/09/23/why-novavax-stock-is-jumping-today/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>What happened\nShares of Novavax (NASDAQ:NVAX) were jumping 9.7% as of 10:48 a.m. EDT on Thursday. There were a couple of catalysts for the stock.\nNovavax and its partner, Serum Institute of India, ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/09/23/why-novavax-stock-is-jumping-today/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"source_url":"https://www.fool.com/investing/2021/09/23/why-novavax-stock-is-jumping-today/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2169698119","content_text":"What happened\nShares of Novavax (NASDAQ:NVAX) were jumping 9.7% as of 10:48 a.m. EDT on Thursday. There were a couple of catalysts for the stock.\nNovavax and its partner, Serum Institute of India, announced Thursday morning that they have filed for World Health Organization emergency use listing of Novavax's COVID-19 vaccine. Also, data from a late-stage clinical study conducted in the U.K. of the vaccine were published in The New England Journal of Medicine. This data showed that Novavax's vaccine achieved an efficacy of 89.7%.\nSo what\nNeither of today's developments was a surprise. However, they were both positive for Novavax and motivated some investors to pile back into the vaccine stock.\nOf the two stories, the EUL filing is the more important for Novavax. An EUL from the WHO is needed to export vaccines to countries that participate in the COVAX Facility. Novavax CEO Stanley Erck stated, \"Today's submission of our protein-based COVID-19 vaccine to WHO for emergency use listing is a significant step on the path to accelerating access and more equitable distribution to countries in great need around the world.\"\nNow what\nIt's uncertain how long the WHO will take to complete its review of Novavax's and SII's EUL filing. In the meantime, investors can look forward to several other key milestones. Novavax is preparing to file for emergency use authorizations in several countries, including the U.K., Canada, Australia, New Zealand, the European Union, and the U.S.","news_type":1,"symbols_score_info":{"NVAX":0.9}},"isVote":1,"tweetType":1,"viewCount":2106,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"lives":[]}